Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2021

May 13, 2021

SELL
$3.94 - $8.19 $113,901 - $236,764
-28,909 Closed
0 $0
Q4 2020

Feb 16, 2021

SELL
$3.99 - $5.7 $47,205 - $67,436
-11,831 Reduced 29.04%
28,909 $118,000
Q3 2020

Nov 12, 2020

SELL
$4.38 - $6.43 $95,137 - $139,666
-21,721 Reduced 34.78%
40,740 $198,000
Q2 2020

Aug 13, 2020

BUY
$3.0 - $6.9 $7,449 - $17,132
2,483 Added 4.14%
62,461 $346,000
Q1 2020

May 13, 2020

BUY
$2.36 - $9.86 $141,548 - $591,383
59,978 New
59,978 $196,000
Q1 2019

May 08, 2019

SELL
$2.62 - $4.44 $138,663 - $234,987
-52,925 Closed
0 $0
Q4 2018

Feb 12, 2019

SELL
$2.28 - $7.15 $18,354 - $57,557
-8,050 Reduced 13.2%
52,925 $132,000
Q3 2018

Nov 13, 2018

SELL
$3.85 - $7.35 $12,320 - $23,520
-3,200 Reduced 4.99%
60,975 $445,000
Q2 2018

Aug 02, 2018

BUY
$3.7 - $5.65 $12,950 - $19,775
3,500 Added 5.77%
64,175 $237,000
Q4 2017

Feb 09, 2018

SELL
$3.4 - $4.15 $32,300 - $39,425
-9,500 Reduced 13.54%
60,675 $218,000
Q3 2017

Nov 14, 2017

SELL
$3.55 - $5.25 $2,485 - $3,675
-700 Reduced 0.99%
70,175 $277,000
Q2 2017

Aug 14, 2017

BUY
N/A
70,875
70,875 $361,000

About APPLIED GENETIC TECHNOLOGIES CORP


  • Ticker AGTC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 67,632,200
  • Description
  • Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Pha...
More about AGTC
Track This Portfolio

Track Connor, Clark & Lunn Investment Management Ltd. Portfolio

Follow Connor, Clark & Lunn Investment Management Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.